Sex Hormone Binding Globulin in Carcinoma of the Prostate

Houghton, Andrew R; Turner, Robert D.; Cooper, Edward H.

doi:10.1111/j.1464-410x.1977.tb04109.x

Cited by 16 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AAT was quantitated in relation to a local standard calibrated with reference to a pure preparation obtained from the American Red Cross National Blood Fractionation Center1 and CPL in relation to standards obtained from Behringwerke AG. Sex Hormone Binding Globulin (SHBG) was measured by a modification of Rosner's method as described by us previously (Houghton, Cooper and Turner, 1977).…”

Section: Methodsmentioning

confidence: 99%

Acute Phase Reactant Proteins in Prostatic Cancer

Ward

Copper

Houghton

1977

British Journal of Urology

Self Cite

View full text Add to dashboard Cite

A profile of acute phase reactant proteins has been studied in patients with cancer of the prostate as an aid to diagnostic staging and therapy control. A linear discriminant function analysis incorporating serum acid phosphatase, prealbumin, alpha1 antitrypsin, alpha1 acid glycoprotein and haptoglobin allows the correct identification of metastatic disease in 88.6% of patients. The profile may also serve to augment other parameters in the assessment of the physiological effect of oestrogen treatment and show whether the prescribed medication is being taken.

show abstract

Section: Methodsmentioning

confidence: 99%

Acute Phase Reactant Proteins in Prostatic Cancer

Ward

Copper

Houghton

1977

British Journal of Urology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The interpretation of plasma testosterone is complicated by the fact that treatment with estrogens increases the production of SHBG. This alters the relationship between the concentration of testosterone that is measured and the biologically important free fraction of testosterone [2,3]. We have, therefore, measured SHBG as well as testosterone and have calculated the free testosterone in each patient.…”

Section: Introductionmentioning

confidence: 99%

Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogens

Levell¹,

Siddall

Rowe

et al. 1987

The Prostate

View full text Add to dashboard Cite

The concentration in serum of testosterone, sex hormone binding globulin (SHBG), and albumin has been measured, and from these measurements free testosterone has been calculated in 75 patients with carcinoma of the prostate treated with either bilateral orchidectomy, stilbestrol, or estramustine phosphate (Estracyt). After exclusion of 3 noncompliant patients, total testosterone did not differ significantly between treatments, but free testosterone was lower in estrogen-treated patients (5.9 +/- 0.9 (SEM) pmol/l, n = 28) compared with the orchidectomized patients (23 +/- 1.4 pmol/l, n = 44) (P less than 0.001); all of the estrogen-treated patients falling in the lower third of the range of the orchidectomized patients. Free testosterone did not change systematically during several years of treatment and there was no evidence of a rise with clinical deterioration. In the 33 patients with metastatic cancer treated with orchidectomy, the third with the lowest free testosterone or total testosterone showed a better survival over 2 years than the two-thirds with higher free or total testosterone; thereafter, the advantage was lost.

show abstract

“…Patients with prostate carcinoma who had not been treated had sex hormone binding globulin (SHBG) levels within the limits of normal when assayed by the Rosner method5 and did not have higher levels than patients with prostatic hyperplasia. 6 There also are no differences in SHBG levels in relation to the stage of carcinoma or whether or not metastases exist.…”

mentioning

confidence: 98%

Plasma sex hormone binding globulin in patients with prostatic carcinoma

Grasso¹,

Buonaguidi²,

Mondina

et al. 1990

Cancer

View full text Add to dashboard Cite

The concentrations of sex hormone binding globulin (SHBG) were measured in the plasma of 56 men, who were 47 to 85 years of age, by time-resolved immunofluorometric assay with a monoclonal antibody. Twenty-five of the men had untreated carcinoma of the prostate and 17 had untreated prostatic hyperplasia. There were 14 healthy control subjects. SHBG levels were significantly higher in patients with prostatic carcinoma (37.6 k 8.4 nmol/l) than in those with prostatic hyperplasia (24.5 -+ 5.2 nmol/l; P < 0.05) or control subjects (14.9 t 2.8 nmol/l; P < 0.01). It is not known why SHBG levels are higher in patients with carcinoma or hyperplasia of the prostate. T like the growth and function of other organs of the male and female reproductive tracts, are under endocrine control, especially by the sex steroids. Because the most important of these for the prostate is the androgens, with dihydrotestosterone (DHT) being the most many attempts have been made to see whether or not the occurrence and the development of prostatic carcinoma result from abnormal androgenic stimulation. Currently, the results of these studies are controversial because men with prostatic cancer had plasma testosterone levels relatively lower than those of men of the same age without the d i~e a s e .~ In addition to assays of total or free hormone levels, the binding capacity of plasma proteins for steroids has been measured for these patients and for those with pathologic features of other hormone-dependent organs. Currently, however, none of these has provided results that are discriminant for carcinoma. Patients with prostate carcinoma who had not been treated had sex hormone binding globulin (SHBG) levels within the limits of normal From the Department of Urology and tBiochemistry Laboratory, Istituto S. Raffaele, Milano; and the *Consiglio Nazionale delle Ricerche, Milano, Italy.The authors thank Mr. Fabio Bravi (Centro Ricerche Italfarmaco, Cinisello, Milano) for statistical analysis of the data in this study.Address for reprints: Marco Grasso, Divisione di Urologia, Via 01-gettina 60, 20 I32 Milano, Italy.Accepted for publication January 3, 1990. when assayed by the Rosner method5 and did not have higher levels than patients with prostatic hyperplasia.6 There also are no differences in SHBG levels in relation to the stage of carcinoma or whether or not metastases exist.Recently, it was suggested that since the plasma binding globulin for steroids is not homogeneous, some method of assay might be able to show differences that others had not been able to show. The use of a suitable assay method has shown that for cancer of another hormone-dependent organ (the breast) there is an increase in steroid binding capacity that is great enough to differentiate the patients from the control subjects, and this assay has been proposed as an indicator for turn or^.^ Starting from this, we measured plasma SHBG concentrations in patients with carcinoma and hyperplasia of the prostate and in healthy control subjects by a new immunofluorometric assay t...

show abstract

Sex Hormone Binding Globulin in Carcinoma of the Prostate

Abstract: Sex Hormone Binding Globulin (SHBG) was measured in 130 patients with carcinoma of the prostate. Its level is raised in patients treated with oestrogen and it is possible that this may be of prognostic significance. The possible relevance of SHBG in oestrogen-treated patients is discussed.

Cited by 16 publications

References 15 publications

Acute Phase Reactant Proteins in Prostatic Cancer

Acute Phase Reactant Proteins in Prostatic Cancer

Relationship of testosterone, sex hormone binding globulin, and calculated free testosterone to subsequent clinical progress in patients with carcinoma of the prostate treated with bilateral orchidectomy or estrogens

Plasma sex hormone binding globulin in patients with prostatic carcinoma

Contact Info

Product

Resources

About